Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of groundbreaking drug candidates aimed at treating human cancers. Established as a significant player in the biotech sector, Curis is renowned for its focus on immuno-oncology and precision oncology therapeutic areas.
Core Business and Pipeline
Curis's pipeline is robust, featuring a number of promising drug candidates. One of its leading drugs is Emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor currently undergoing clinical trials. The trials include the Phase 1/2 TakeAim Lymphoma study, which targets hematologic malignancies such as non-Hodgkin's lymphoma, and the Phase 1/2 TakeAim Leukemia study aimed at acute myeloid leukemia and myelodysplastic syndrome. Emavusertib has already received Orphan Drug Designation from the U.S. Food and Drug Administration.
Curis is also investigating other candidates such as CUDC-907, which focuses on relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene, and other small molecule antagonists like CA-170 and CA-327, designed to inhibit pathways such as PD1, VISTA, and TIM3.
Collaborations & Partnerships
Curis has forged a strategic collaboration with Aurigene, granting it exclusive licenses to several promising molecules. This partnership enhances Curis's ability to innovate in the areas of immuno-oncology and precision oncology, specifically with oral small molecule antagonists. Additionally, Curis has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma under the Roche Group.
Recent Achievements and Financial Condition
Curis has recently presented data from multiple clinical studies at prestigious conferences such as the American Society of Hematology (ASH) and the European Hematology Association (EHA), showcasing promising results from its ongoing trials. The company reported a net loss of $47.4 million for the year ended December 31, 2023, but continues to maintain a strong cash position with $56.3 million in cash, cash equivalents, and investments.
Curis's ongoing research and development efforts are backed by substantial funding and strategic partnerships, enabling the company to sustain its operations and advance its pipeline into the year 2025.
For more information, visit Curis's website at www.curis.com.
Curis (NASDAQ: CRIS) presented additional data from the TakeAim Leukemia study of emavusertib in relapsed/refractory Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting. The updated results include data from 21 patients with FLT3 mutation treated at the Recommended Phase 2 Dose of 300 mg BID.
Among 19 response-evaluable patients, 10 showed objective responses: 6 complete remissions (CR), 2 CR with incomplete/partial hematological recovery, and 2 morphologic leukemia-free state. Prior therapies of responders included Venetoclax, HMA, and FLT3i. Two patients proceeded to allogenic stem cell transplantation, with 7 of 10 responses observed at first assessment.
Curis Inc (NASDAQ: CRIS) reported Q3 2024 financial results with a net loss of $10.1 million ($1.70 per share), compared to $12.2 million in Q3 2023. Revenues were $2.9 million, primarily from Erivedge® royalties. The company completed a registered direct offering with net proceeds of $10.8 million. Clinical progress includes promising data from the TakeAim Lymphoma study, showing 3 complete responses and 1 unconfirmed complete response in PCNSL patients. Cash position stands at $31.6 million, expected to fund operations into mid-2025.
Curis (NASDAQ: CRIS) has announced it will release its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. The biotechnology company, which focuses on developing emavusertib (CA-4948), an oral IRAK4 inhibitor, will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone or access the live audio webcast through the investor section of the Curis website.
Curis (NASDAQ: CRIS) has announced a $12.1 million financing through a registered direct offering and concurrent private placement. The company will issue 2,398,414 shares of common stock and unregistered warrants to purchase an equal number of shares. The warrants have an exercise price of $4.92 per share, are immediately exercisable, and expire in five years. The combined purchase price is $5.045 per share and warrant. The proceeds will fund research, development, working capital, and general corporate purposes. The offering is expected to close around October 30, 2024.
Curis, Inc. (NASDAQ: CRIS) announces the 3rd Annual Symposium on IRAK4 in Cancer, scheduled for September 26, 2024. The virtual event, hosted by Dr. Eric S. Winer and Dr. Grzegorz S. Nowakowski, will focus on IRAK4 as an emerging target in treating hematologic malignancies and solid tumors. The symposium will feature updated data for 10 evaluable R/R PCNSL patients as of July 10, 2024. Curis aims to enroll 15-20 patients in the PCNSL study by year-end.
The event will bring together experts to discuss the potential of IRAK4 inhibition in cancer, including current clinical studies of emavusertib (CA-4948), Curis's orally available, small molecule IRAK4 inhibitor. Presentations will cover the biology of the IRAK4 pathway and its inhibition in cancer therapy development. The symposium is free and open to the public, offering insights into this promising area of oncology research.
Curis Inc (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. James Dentzer, President and CEO of Curis, will engage in a fireside chat on September 17, 2024, at 4:15 PM ET.
The event will be accessible via webcast through the Cantor link and on the Curis website in the Investors section. This participation underscores Curis's commitment to engaging with the investment community and showcasing its progress in developing innovative therapies for cancer treatment.
Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its participation in two upcoming healthcare conferences in September 2024. James Dentzer, President and CEO, will represent Curis at these events:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9-11): Company presentation on Sept. 11 at 1:00 pm ET.
2. 2024 Cantor Fitzgerald Global Healthcare Conference (Sept. 17-19): Fireside chat on Sept. 17 at 3:05 pm ET.
Webcasts for both presentations will be available on the Curis website in the 'Investors' section, providing investors with opportunities to gain insights into the company's progress and strategy.
Curis Inc. (NASDAQ: CRIS) reported Q2 2024 financial results and operational updates. Key highlights include:
1. European Commission granted Orphan Drug Designation to emavusertib for PCNSL treatment.
2. Initial data for 15-20 R/R PCNSL patients expected by late 2024.
3. Positive preliminary data in R/R AML patients with FLT3 and SF mutations.
4. Q2 2024 net loss of $11.8 million ($2.03 per share) vs $12.0 million ($2.47 per share) in Q2 2023.
5. Revenues increased to $2.5 million in Q2 2024 from $2.2 million in Q2 2023.
6. Cash position of $28.4 million as of June 30, 2024, expected to fund operations into Q1 2025.
Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its plans to release second quarter 2024 financial and operating results on August 1, 2024, at 8:00 a.m. ET. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Interested parties can join the call by dialing (800)-836-8184 from the US or (646)-357-8785 from other locations. A live audio webcast will be available on the investor section of the Curis website, with a replay accessible later at www.curis.com.
Curis, a biotechnology company listed on NASDAQ under the ticker CRIS, announced that its President and CEO, James Dentzer, will present at the Jones Healthcare Seaside Summit 2024. The presentation is scheduled for July 15, 2024, at 8:00 a.m. PT (11:00 a.m. ET). Curis focuses on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor. A live webcast and an archived replay of the presentation will be accessible through the Events & Presentations section of Curis's website.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
What is Curis Inc.'s focus in the biotechnology sector?
What are some of the key drug candidates in Curis's pipeline?
What significant collaborations does Curis have?
What is the current status of Emavusertib's clinical trials?
How is Curis performing financially?
What recent achievements has Curis reported?
What is the significance of Curis's collaboration with Aurigene?
What role does Genentech play in Curis's portfolio?
What are Curis's future plans for its drug pipeline?
Where can I find more information about Curis Inc.?
